deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT01479842

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

A Phase I, Dose-escalation Trial of Rituxan and Bendamustine in Combination With Bruton's Tyrosine Kinase Inhibitor, PCI-32765, in Patients With Relapsed Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Indolent Non-Hodgkin's Lymphoma

Sponsor: Kami Maddocks, MD

Conditions Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Nodal Marginal Zone B-cell Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Splenic Marginal Zone Lymphoma Waldenstrom Macroglobulinemia
Interventions BTK inhibitor PCI-32765 bendamustine hydrochloride laboratory biomarker analysis pharmacogenomic studies pharmacological study rituximab
Updated 16 times since 2017 Last updated: Oct 13, 2025 Started: Mar 26, 2014 Primary completion: Mar 1, 2026 Completion: Mar 1, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01479842, this PHASE1 trial focuses on Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue and Nodal Marginal Zone B-cell Lymphoma and remains ongoing. Sponsored by Kami Maddocks, MD, it has been updated 16 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Dec 2017 · 10 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Oct 2020 · 20 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jul 2022 · 16 months · monthly snapshot~Jul 2022 – ~Dec 2023 · 17 months · monthly snapshot~Dec 2023 – ~Mar 2024 · 3 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Jun 2025 · 3 months · monthly snapshot~Jun 2025 – ~Nov 2025 · 5 months · monthly snapshot~Nov 2025 – present · 9 months · monthly snapshot

Change History

16 versions recorded

  1. Nov 2025 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Jun 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Mar 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Sep 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE1

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 11 earlier versions

  1. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  2. Dec 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1

  3. Jul 2022 — Dec 2023 [monthly]

    Active Not Recruiting PHASE1

  4. Mar 2021 — Jul 2022 [monthly]

    Active Not Recruiting PHASE1

  5. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1

  6. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  7. Feb 2019 — Oct 2020 [monthly]

    Active Not Recruiting PHASE1

  8. Jun 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE1

  9. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  10. Feb 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE1

  11. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Kami Maddocks, MD
  • Pharmacyclics LLC.
Data source: Ohio State University Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations